JAK Inhibitor Drug Reverses Alopecia Areata
The use of JAK inhibitor drugs have been shown to be effective in the treatment of Alopecia Areata. Janus Kinase Inhibitors (JAK) are drugs which supress the functions of the JAK enzyme, a critical en\This is an inherited ‘autoimmune’ disease that causes the body to reject regional areas of hair in various parts of the body. It is usually found in the scalp, but face and other body parts can show this problem. Two drug have been tested effectively, they are (1) ruxolitinib, a medication used in the treatment of certain malignancies such as bone marrow cancers and (2) tofacitinib, a drug used in the treatment of Rheumatoid Arthritis. This is an early report from the Journal of Investimationo/Insights 2016.
TOFACIB
This is an answer from the manufacturer of the cream when asked what is the difference between Baricitnib and Decernotinib and Ruxolitinib and Tofacitinib /
Hi,
1) baricitinib – “Despite widespread expectations that the FDA would approve baricitinib for RA, in April 2017, the FDA issued a rejection, citing concerns about dosing and safety.”
2) decernotinib – not approved in FDA(The application was not left), and i not saw any research about that, everything is in the initial stage, but I hope that this will be useful
FDA APPROVED TOFACITINIB AND RUXOLITINIB ONLY!
Difirent of which JAK subtypes they inhibit:
TOFA JAK1 and JAK3
RUXO JAK1 and JAK2